Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 0.41 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL101838 | 0.91 | RAB9A (0.44) | CHRM3CHRM2CHRM1RAB9APOLB | |
| Iodide SCHEMBL661715 | 0.90 | CHRM3 (0.39) | CHRM3CHRM2CHRM1RAB9APOLB | |
| Iodide SCHEMBL100122 | 0.90 | CHRM3 (0.39) | CHRM3CHRM2CHRM1 | |
| SCHEMBL662182 | 0.88 | CHRM3 (0.55) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL99285 | 0.87 | NPC1 (0.42) | CHRM3CHRM2CHRM1RAB9A | |
| Iodide SCHEMBL99484 | 0.86 | POLB (0.41) | CHRM3CHRM2CHRM1RAB9APOLB | |
| Iodide SCHEMBL101146 | 0.85 | CHRM3 (0.43) | CHRM3CHRM2CHRM1 | |
| Iodide SCHEMBL97714 | 0.85 | CHRM3 (0.43) | CHRM3CHRM2CHRM1HCAR2 | |
| Iodide SCHEMBL101246 | 0.84 | CHRM3 (0.43) | CHRM3HCAR2 | |
| Iodide SCHEMBL100421 | 0.84 | LTB4R (0.48) | CHRM3RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | claimed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | CHRM3 9/4885CHRM1 25/4885CHRM2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.